Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1623 1691 1693
This examiner grants 44% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17965573 | GLYCOLIPID COMPOSITIONS AND METHODS OF USE | Final Rejection | President and Fellows of Harvard College |
| 18256401 | REDUCTION OF RANCIDITY OF VEGETABLE OILS | Final Rejection | DSM IP Assets B.V. |
| 18226071 | Methods and Compositions for Treating Leucine Rich Repeat Kinase 2 (LRRK2)-Associated Disorder or Condition | Non-Final OA | University of Connecticut |
| 17754102 | Methods of Treatments to Prolong Gestation and Complications of Menstruation or Gestation | Final Rejection | Trustees of Boston University |
| 17759597 | METHOD FOR PRODUCING NUCLEIC ACID OLIGOMER | Final Rejection | SUMITOMO CHEMICAL COMPANY, LIMITED |
| 17779706 | SYNTHESIS OF 3 -RNA OLIGONUCLEOTIDES | Non-Final OA | ALNYLAM PHARMACEUTICALS, INC. |
| 17594415 | N-1 BRANCHED ALKYL SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS, COMPOSITIONS, AND METHODS | Non-Final OA | 3M INNOVATIVE PROPERTIES COMPANY |
| 17597878 | ANTICANCER AGENTS | Final Rejection | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. |
| 18109021 | CORONAVIRUS TREATMENT COMPOSITION AND METHOD | Non-Final OA | University of Tennessee Research Foundation |
| 17431462 | Methods for purifying bacterial polysaccharides | Non-Final OA | Pfizer Inc. |
| 18288397 | MALTOSIDE-, LACTOBIONAMIDE-, MONOGLUCOSIDE-, BRANCHED DIGLUCOSIDE-, SULFOBETAINE-, SULFATE- OR AMINOOXIDE-BASED PERFLUORINATED DETERGENTS AND THEIR USE IN MEMBRANE-PROTEINS APPLICATIONS | Non-Final OA | ECOLE NATIONALE SUPERIEURE DE CHIMIE DE MONTPELLIER |
| 18256057 | FIBRE MIXTURE FOR YOUNG CHILDREN | Final Rejection | N.V. Nutricia |
| 18284177 | PURIFICATION AND RECYCLING OF mRNA NUCLEOTIDE CAPS | Non-Final OA | ModernaTX, Inc. |
| 18039107 | IMMUNOTHERAPY FOR CANCER | Non-Final OA | THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOL |
| 17761376 | Antibiotic Compounds | Non-Final OA | UNIVERSITEIT LEIDEN |
| 17422638 | COMPOSITIONS AND METHODS FOR INDUCING OR SUPPLEMENTING SOCS3 TO ABROGATE TUMOR GROWTH AND PROLIFERATIVE RETINOPATHY | Non-Final OA | Children's Medical Center Corporation |
| 17911712 | Compounds Useful in HIV Therapy | Final Rejection | VIIV HEALTHCARE COMPANY |
| 18259146 | NOVEL GALACTOSIDE INHIBITOR OF GALECTINS | Non-Final OA | GALECTO BIOTECH AB |
| 18142198 | COMPOSITION AND METHODS FOR GENERATING A DERMAL FILLER | Final Rejection | Allure Medical Spa PLLC |
| 18135229 | Method and compounds for inhibiting the MCM complex and their application in cancer treatment | Non-Final OA | Macau University Of Science And Technology |
| 18295247 | METHYLCOBALAMIN OPHTHALMIC PREPARATION AND USE THEREOF | Non-Final OA | EYE INSTITUTE OF SHANDONG FIRST MEDICAL UNIVERSITY |
| 17910224 | ADJUVANT COMPOUNDS, SALT FORMS, AND FORMULATIONS | Non-Final OA | ADJUVANCE TECHNOLOGIES, INC. |
| 18012694 | SAPONIN DERIVATIVES FOR USE IN MEDICINE | Non-Final OA | SAPREME TECHNOLOGIES B.V. |
| 17629796 | Saponin derivatives with improved therapeutic window | Non-Final OA | Sapreme Technologies B.V. |
| 18041134 | MACROPHAGE TARGETING DRUG CONJUGATES | Non-Final OA | P.I.F. Entrepreneurs Ltd. |
| 17782596 | TRIANTENNARY N-ACETYLGALACTOSAMINE MODIFIED HYDROXYL POLYAMIDOAMINE DENDRIMERS AND METHODS OF USE THEREOF | Non-Final OA | Ashvattha Therapeutics, Inc. |
| 17920183 | METHODS AND REGIMENS FOR THE TREATMENT OF HEMATOLOGICAL CANCER | Final Rejection | Biosight Ltd. |
| 17914576 | NICOTINAMIDE MONONUCLEOTIDE DERIVATIVES FOR THE TREATMENT OF BACTERIAL INFECTIONS | Final Rejection | NUVAMID SA |
| 17796904 | XANTHAN-BASED OPHTHALMIC TOPICAL FORMULATIONS WITH A REDUCED DOSAGE REGIMEN | Final Rejection | SIFI S.P.A. |
| 17753178 | METHOD, COMPOSITION AND KIT FOR SIZE SELECTIVE ENRICHMENT OF NUCLEIC ACIDS | Non-Final OA | PHASE SCIENTIFIC INTERNATIONAL, LTD. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy